MoonLake Immunotherapeutics (MLTX) Other financing activities (2021 - 2026)

MoonLake Immunotherapeutics' Other financing activities history runs 6 years deep, the most recent figure standing at $170000.0 for Q1 2026.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $170000.0 in Q1 2026; TTM through Mar 2026 was $72.6 million, a 37.87% increase from a year earlier, with the FY2025 full-year figure at $72.4 million, up 37.79% from the prior year.
• Other financing activities retreated to $170000.0 in Q1 2026 per MLTX's latest filing, from $71.9 million in the prior quarter.
• Across five years, Other financing activities topped out at $482.5 million in Q4 2023 and bottomed at -$3791.0 in Q2 2022.
• The 5-year median for Other financing activities is $170000.0 (2026), against an average of $67.5 million.
• Across the five-year window, Other financing activities sank 89.11% in 2024 and jumped 316.22% in 2025, its largest moves.
• Year by year, Other financing activities stood at -$3791.0 in 2022, then jumped by 12726399.13% to $482.5 million in 2023, then sank by 89.11% to $52.5 million in 2024, then surged by 36.88% to $71.9 million in 2025, then sank by 99.76% to $170000.0 in 2026.
• Per Business Quant, the three latest MLTX Other financing activities figures stand at $170000.0 (Q1 2026), $71.9 million (Q4 2025), and $380000.0 (Q3 2025).